Zydus Cadila begins human trials of its COVID-19 vaccine, aims for an early 2021 launch

The company said in the preclinical stage the vaccine was found to be safe, immunogenic and well-tolerated. It was also able to produce neutralising antibodies in animal studies, a key requirement for a vaccine. In the phase-I and II trials, the company will assess the safety, tolerability and immunogenicity of the vaccine.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3980gX2
via IFTTT